middle.news
Biotron’s BIT-HBV001 Targets Hepatitis Delta, Broadening Treatment Horizons
9:06am on Wednesday 18th of March, 2026 AEDT
•
Healthcare
Read Story
Biotron’s BIT-HBV001 Targets Hepatitis Delta, Broadening Treatment Horizons
9:06am on Wednesday 18th of March, 2026 AEDT
Key Points
BIT-HBV001 inhibits Hepatitis Delta Virus replication by ~85%
Co-infection with HBV and HDV linked to severe liver disease
Sedarex acquisition fully integrated into Biotron operations
Regulatory submissions for SedRx progressing in Europe and USA
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
BIOTRON (ASX:BIT)
OPEN ARTICLE